Patent RU-2342366-C2 (RU)
Title: Pyrimidinsulfonamide derivatives as chemokine receptor modulators, methods of their obtaining (versions) and application
Inventor: EHBDEN MARK RICHARD
IPC: A61P1/04
Filed: 2003-07-23
Granted: 2008-12-27
Abstract: FIELD: chemistry, pharmacology. 
     SUBSTANCE: invention relates to novel compounds of formula (I), its pharmaceutically acceptable salts, possessing qualities of chemokine receptor modulators. Compounds can be applied for asthma, allergic rhinitis, COLD, inflammatory intestinal disease, irritated intestine syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis or cancer. In compound of formula (I)  , R 1  represents group selected from C 1-8 alkyl, said group is possibly substituted with 1, 2 or 3 substituents, independently selected from -OR 4  , -NR 5 R 6  , phenyl, phenyl is possibly substituted with 1, 2 or 3 substituents, independently selected from halogeno, -OR 4 ,-NR 5 R 6 ,-SR 10 ,C 1-6 alkyl and trifluoromethyl; R 2  represents group selected from C 1-8 alkyl, said group is substituted with 1, 2 or 3 substituents, independently selected from hydroxy, amino, C 1-6 alkoxy, C 1-6 alkylamino, di(C 1-6 alkyl)amino, N-(C 1-6 alkyl)-N-(phenyl)amino; R 3  represents hydrogen, R 4  represents hydrogen or group selected from C 1-6 alkyl and phenyl, R 5  and R 6 , independently, represent hydrogen or group selected from C 1-6 alkyl and phenyl, said group being probably substituted with 1, 2 or 3 substituents, independently selected from -OR 14 , -NR 15 R 16 , -COOR 14 ,-CONR 15 R 16 , or R 5  and R 6  together with nitrogen atom, to which they are bound, form 4-7-member saturated heterocyclic ring system, possibly containing additional heteroatom, selected from oxygen and nitrogen atoms, ring possibly being substituted with 1, 2 or 3 substituents, independently selected from -OR 14 , -COOR 14 ,-NR 15 R 16   , CONR 15 R 16  and C 1-6 alkyl; R 10  represents hydrogen or group selected from C 1-6 alkyl or phenyl; and each from R 7 , R 8 , R 9 , R 14 , R 15 , R 16  independently represents hydrogen, C 1-6 alkyl or phenyl; X represents hydrogen, halogeno; R x  represents trifluoromethyl, -NR 5  R 6  , phenyl, naphtyl, heteroaryl, heteroring can be partly or fully saturated, and one or more ring carbon atoms can form carbonyl group, each phenyl or heteroaryl group being possibly substituted with 1, 2 or 3 substituents, independently selected from halogeno, cyano, -OR 4 , -NR 5 R 6 , -CONR 5 R 6 , -COR 7 , -COOR 7 , -NR 8 COR 9 , -SR 10 , -SO 2 R 10 , -SO 2 NR 5 R 6 , -NR 8 SO 2 R 9 , C 1-6 alkyl or trifluoromethyl; or R x  represents group selected from C 1-6 alkyl, said group being possibly substituted with 1, 2 or 3 substituents, independently selected from halogeno, -OR 4 , -NR 5 R 6 , phenyl or heteroaryl, where heteroaryl represents monocyclic or bicyclic aryl ring, containing from 5 to 10 ring atoms, from which 1, 2 or 3 ring atoms are selected from nitrogen, sulfur or oxygen. Invention also relates to methods of obtaining compounds, versions, pharmaceutical composition and application for manufacturing medications using compounds of invention. 
     EFFECT: obtaining novel compounds of formula (I), its pharmaceutically acceptable salts, possessing properties of chemokine receptor moduators. 
     25 cl, 138 ex